Why DELFI Diagnostics’ New York approval could shake up the lung cancer screening market
DELFI Diagnostics can now offer FirstLook Lung in all 50 states. Find out what this means for blood-based cancer screening.
Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring
MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.
Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Why PanGIA Biotech’s urine biopsy data may matter more than the headline sensitivity figure suggests
PanGIA Biotech reported 97.8% sensitivity in a urine-based prostate cancer study. Read what the data changes and what risks still remain.
Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics
Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.
How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026
Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.
How Adela’s tissue-free ctDNA methylation test could reshape monitoring of immunotherapy outcomes
Adela’s methylome blood test may help detect immunotherapy response earlier in cancer care. Discover what the latest study reveals for clinicians and diagnostics markets.
Lucid Diagnostics gains strategic VA partnership to deploy EsoGuard across veteran programs
Discover how Lucid Diagnostics is expanding EsoGuard adoption with a new U.S. Veterans Affairs contract for early cancer screening.
Guardant Health and Merck sign global deal to co-develop cancer companion diagnostics
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
What Pillar Biosciences’ China move means for decentralized oncology diagnostics
Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround […]